BIVI (BioVie) חוב לטווח קצר להון

BioVie Inc. (BIVI) is establishing strategic alliances with clinics to test therapies for neurodegenerative disorders. The firm's financial foundation relies on a debt-free balance sheet and strict control over capital expenditures, which protects its cirrhosis research and development. The current metric stands at 0.01. This price action chart below illustrates the trajectory of the company, which is developing treatments for brain inflammation and liver pathologies.

This indicator measures the proportion of short-term borrowings relative to equity, allowing for an assessment of liquidity risk in the event of a sharp shift in market conditions. Analyzing the trend of loans with maturities of up to one year relative to equity is critically important for BioVie Inc. (BIVI), as a high debt load amid fierce competition with biotech behemoths could limit the resources available to complete costly research.